AquaBounty (AQB) 10-Q 5 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 04, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	Aquabounty Technologies, Inc.
Entity Central Index Key	0001603978
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		21,605,322

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,412,921	$ 2,990,196
Certificate of deposit	12,712	12,361
Other receivables	73,340	115,982
Inventory	477,077	76,109
Prepaid expenses and other current assets	391,561	315,969
Total current assets	7,367,611	3,510,617
Property, plant and equipment, net	24,780,705	23,716,768
Right of use assets, net	413,235	0
Definite-lived intangible assets, net	161,014	171,292
Indefinite-lived intangible assets	191,800	191,800
Other assets	45,001	80,583
Total assets	32,959,366	27,671,060
Current liabilities:
Accounts payable and accrued liabilities	1,102,621	824,900
Other current liabilities	61,315	20,423
Current debt	149,069	71,613
Total current liabilities	1,313,005	916,936
Long-term lease obligations	368,739	0
Long-term debt	4,397,539	3,519,821
Total liabilities	6,079,283	4,436,757
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 50,000,000 shares authorized; 21,605,322 (2018: 15,098,837) shares outstanding	21,605	15,099
Additional paid-in capital	156,022,668	142,707,957
Accumulated other comprehensive loss	(440,738)	(574,186)
Accumulated deficit	(128,723,452)	(118,914,567)
Total stockholders’ equity	26,880,083	23,234,303
Total liabilities and stockholders’ equity	$ 32,959,366	$ 27,671,060

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, share authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	21,605,322	15,098,837

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues
Product revenues	$ 0	$ 10,938	$ 140,371	$ 77,933
Costs and expenses
Product costs	0	8,874	120,605	72,393
Sales and marketing	206,256	64,971	381,637	222,999
Research and development	446,582	804,758	1,923,512	2,663,397
General and administrative	2,346,754	1,852,362	7,489,622	5,067,226
Total costs and expenses	2,999,592	2,730,965	9,915,376	8,026,015
Operating loss	(2,999,592)	(2,720,027)	(9,775,005)	(7,948,082)
Other income (expense)
Gain on disposal of equipment	0	0	8,548	11,745
Interest expense	(17,933)	(5,169)	(45,483)	(15,854)
Other income (expense), net	(697)	(1,832)	3,055	(5,773)
Total other income (expense)	(18,630)	(7,001)	(33,880)	(9,882)
Net loss	(3,018,222)	(2,727,028)	(9,808,885)	(7,957,964)
Other comprehensive income (loss):
Foreign currency translation income (loss)	(38,892)	84,711	133,448	(113,218)
Total other comprehensive income (loss)	(38,892)	84,711	133,448	(113,218)
Comprehensive loss	$ (3,057,114)	$ (2,642,317)	$ (9,675,437)	$ (8,071,182)
Basic and diluted net loss per share (in dollars per share)	$ (0.14)	$ (0.21)	$ (0.50)	$ (0.64)
Weighted average number of common shares - basic and diluted (in shares)	21,604,072	12,848,376	19,556,607	12,528,995

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning Balance, issued and outstanding (in shares) at Dec. 31, 2017		8,895,094
Beginning Balance at Dec. 31, 2017	$ 17,980,689	$ 8,895	$ 126,718,186	$ (213,884)	$ (108,532,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,449,787)				(2,449,787)
Other comprehensive income (loss)	(112,118)			(112,118)
Issuance of common stock, net (in shares)		3,692,307
Issuance of common stock, net	10,616,048	$ 3,692	10,612,356
Exercise of warrants (in shares)		76,981
Exercise of warrants	250,188	$ 77	250,111
Share based compensation (in shares)		11,151
Share based compensation	48,545	$ 11	48,534
Ending Balance, issued and outstanding (in shares) at Mar. 31, 2018		12,675,533
Ending Balance at Mar. 31, 2018	26,333,565	$ 12,675	137,629,187	(326,002)	(110,982,295)
Beginning Balance, issued and outstanding (in shares) at Dec. 31, 2017		8,895,094
Beginning Balance at Dec. 31, 2017	17,980,689	$ 8,895	126,718,186	(213,884)	(108,532,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,957,964)
Other comprehensive income (loss)	(113,218)
Ending Balance, issued and outstanding (in shares) at Sep. 30, 2018		12,848,376
Ending Balance at Sep. 30, 2018	21,529,165	$ 12,848	138,333,891	(327,102)	(116,490,472)
Beginning Balance, issued and outstanding (in shares) at Mar. 31, 2018		12,675,533
Beginning Balance at Mar. 31, 2018	26,333,565	$ 12,675	137,629,187	(326,002)	(110,982,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,781,149)				(2,781,149)
Other comprehensive income (loss)	(85,811)			(85,811)
Exercise of warrants (in shares)		172,843
Exercise of warrants	561,740	$ 173	561,567
Share based compensation (in shares)
Share based compensation	71,544		71,544
Ending Balance, issued and outstanding (in shares) at Jun. 30, 2018		12,848,376
Ending Balance at Jun. 30, 2018	24,099,889	$ 12,848	138,262,298	(411,813)	(113,763,444)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,727,028)				(2,727,028)
Other comprehensive income (loss)	84,711			84,711
Share based compensation	71,593		71,593
Ending Balance, issued and outstanding (in shares) at Sep. 30, 2018		12,848,376
Ending Balance at Sep. 30, 2018	21,529,165	$ 12,848	138,333,891	(327,102)	(116,490,472)
Beginning Balance, issued and outstanding (in shares) at Dec. 31, 2018		15,098,837
Beginning Balance at Dec. 31, 2018	23,234,303	$ 15,099	142,707,957	(574,186)	(118,914,567)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(2,763,932)				(2,763,932)
Other comprehensive income (loss)	87,552			87,552
Issuance of common stock, net (in shares)		3,345,282
Issuance of common stock, net	6,609,655	$ 3,345	6,606,310
Exercise of warrants (in shares)		76,797
Exercise of warrants	250,424	$ 77	250,347
Share based compensation (in shares)		176,561
Share based compensation	138,498	$ 176	138,322
Ending Balance, issued and outstanding (in shares) at Mar. 31, 2019		18,697,477
Ending Balance at Mar. 31, 2019	27,556,500	$ 18,697	149,702,936	(486,634)	(121,678,499)
Beginning Balance, issued and outstanding (in shares) at Dec. 31, 2018		15,098,837
Beginning Balance at Dec. 31, 2018	23,234,303	$ 15,099	142,707,957	(574,186)	(118,914,567)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(9,808,885)
Other comprehensive income (loss)	133,448
Ending Balance, issued and outstanding (in shares) at Sep. 30, 2019		21,605,322
Ending Balance at Sep. 30, 2019	26,880,083	$ 21,605	156,022,668	(440,738)	(128,723,452)
Beginning Balance, issued and outstanding (in shares) at Mar. 31, 2019		18,697,477
Beginning Balance at Mar. 31, 2019	27,556,500	$ 18,697	149,702,936	(486,634)	(121,678,499)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,026,731)				(4,026,731)
Other comprehensive income (loss)	84,788			84,788
Issuance of common stock, net (in shares)		2,901,078
Issuance of common stock, net	5,785,693	$ 2,901	5,782,792
Share based compensation (in shares)
Share based compensation	318,218		318,218
Ending Balance, issued and outstanding (in shares) at Jun. 30, 2019		21,598,555
Ending Balance at Jun. 30, 2019	29,718,468	$ 21,598	155,803,946	(401,846)	(125,705,230)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,018,222)				(3,018,222)
Other comprehensive income (loss)	(38,892)			(38,892)
Exercise of warrants (in shares)		6,767
Exercise of warrants	21,993	$ 7	21,986
Share based compensation	196,736		196,736
Ending Balance, issued and outstanding (in shares) at Sep. 30, 2019		21,605,322
Ending Balance at Sep. 30, 2019	$ 26,880,083	$ 21,605	$ 156,022,668	$ (440,738)	$ (128,723,452)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities
Net loss	$ (9,808,885)	$ (7,957,964)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	928,476	557,718
Share-based compensation	653,452	191,682
Gain on disposal of equipment	(8,548)	(11,745)
Changes in operating assets and liabilities:
Other receivables	45,880	97,353
Inventory	(400,716)	97,897
Prepaid expenses and other assets	(43,404)	210,796
Accounts payable and accrued liabilities	345,569	(654,997)
Net cash used in operating activities	(8,288,176)	(7,469,260)
Investing activities
Purchase of property, plant and equipment	(1,824,831)	(3,375,306)
Proceeds from sale of equipment	8,548	21,758
Other investing activities	12	0
Net cash used in investing activities	(1,816,271)	(3,353,548)
Financing activities
Proceeds from issuance of debt	900,767	0
Repayment of term debt	(57,001)	(43,437)
Proceeds from the issuance of common stock and warrants, net	12,395,348	10,616,048
Proceeds from the exercise of stock options and warrants, net	272,416	811,928
Net cash provided by financing activities	13,511,530	11,384,539
Effect of exchange rate changes on cash and cash equivalents	15,642	(23,921)
Net change in cash and cash equivalents	3,422,725	537,810
Cash and cash equivalents at beginning of period	2,990,196	492,861
Cash and cash equivalents at the end of period	6,412,921	1,030,671
Supplemental disclosure of cash flow information and non-cash transactions:
Interest paid in cash	45,483	15,854
Property and equipment included in accounts payable and accrued liabilities	119,541	512,497
Acquisition of equipment under debt arrangement	$ 0	$ 74,555

Nature of business and organiza

Nature of business and organization	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and organization	Nature of business and organization AquaBounty Technologies, Inc. (the “Parent” and, together with its subsidiaries, the “Company”) was incorporated in December 1991 in the State of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm‑raised Atlantic salmon that exhibit growth rates that are substantially faster than traditional salmon. In 2015, the Parent obtained approval from the US Food and Drug Administration (the “FDA”) for the production, sale, and consumption of its AquAdvantage Salmon product in the United States. In 2016, the Parent obtained approval from Health Canada for the sale and consumption of its AquAdvantage Salmon product in Canada. Previously, in 2013, the Parent obtained approval from Environment Canada for the production of the product. AQUA Bounty Canada Inc. (the “Canadian Subsidiary”) was incorporated in January 1994 for the purpose of establishing a commercial biotechnology laboratory to conduct research and development programs related to the Parent’s technologies and to commercialize the Parent’s products in Canada. AquaBounty Panama, S. de R.L. (the “Panama Subsidiary”) was incorporated in May 2008 in Panama for the purpose of conducting commercial trials of the Parent’s products. With the regulatory approval of the Company’s farms in Indiana and Rollo Bay, the site in Panama was no longer needed for commercial trials. Operations at the site ceased in May 2019. AquaBounty Farms, Inc. (the “U.S. Subsidiary”) was incorporated in December 2014 in the State of Delaware for the purpose of conducting field trials and commercializing the Parent’s products in the United States. AquaBounty Farms Indiana LLC (the “Indiana Subsidiary”), which is wholly owned by the U.S. Subsidiary, was formed in June 2017 in the State of Delaware for the purpose of operating its aquaculture facility in Albany, Indiana. AquaBounty Brasil Participações Ltda. (the “Brazil Subsidiary”) was incorporated in May 2015 for the purpose of conducting field trials and commercializing the Parent’s products in Brazil.

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The unaudited interim consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC; and AquaBounty Brasil Participações Ltda. All inter-company transactions and balances have been eliminated upon consolidation. The unaudited interim consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2018 . The unaudited interim consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of September 30, 2019 , and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. Going Concern Uncertainty and Management’s Plan The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In the Company’s Annual Report on Form 10‑K for December 31, 2018, management stated that there was substantial doubt about the Company’s ability to continue as a going concern due to its limited capital resources, and the Company’s independent registered public accounting firm emphasized this matter in its report to the shareholders and the Board of Directors. At that time, management prepared a plan to mitigate this doubt, which included an equity raise that subsequently provided the Company with $12.4 million of net new funds in 2019. At September 30, 2019 , the Company’s cash balance totaled $6.4 million . Management has evaluated the Company’s cash resources in view of its planned spending for ongoing operations, capital expenditures, and working capital for the next twelve months from the filing date and has determined that its current funds will be exhausted by June 30, 2020. As a result, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. To mitigate this doubt, management plans to seek additional financing in the form of equity or debt, partnerships, or other non-dilutive transactions to fund the Company’s cash requirements. However, the Company may not be able to raise additional financing or to do so at terms that are acceptable. In this event, management has the ability to reduce expenditures, slow down or delay capital spending, and divest assets in order to ensure its cash will extend through the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of the above uncertainty. Net loss per share Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Basic net loss is based solely on the number of Common Shares outstanding during the period. Fully diluted net loss per share includes the number of shares of common stock issuable upon the exercise of warrants and options with an exercise price less than the fair value of the common stock. Since the Company is reporting a net loss for all periods presented, all potential common shares are considered anti‑dilutive and are excluded from the calculation of diluted net loss per share. Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016‑02, “Leases,” which requires a lessee to recognize lease liabilities for the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and right-of-use assets, representing the lessee’s right to use, or control the use of, specified assets for the lease term. The ASU is effective for fiscal years beginning after December 15, 2018. The Company adopted FASB ASU 2016-02 for lease accounting on January 1, 2019 and recognized a lease liability of $532 thousand and a corresponding right-of-use asset of $512 thousand . Management calculated the lease liability based on the net present value of the remaining lease payments on the date of adoption using a weighted average discount rate of 8% . As most of the Company’s leases did not provide an implicit interest rate, management used an estimated incremental borrowing rate. The adoption did not result in any cumulative-effect adjustment to beginning retained earnings. The Company leases certain facilities, property, and equipment under noncancelable operating leases. A determination is made if an arrangement is a lease at its inception, and leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. For operating leases, expense is recognized on a straight-line basis over the lease term. The Company has agreements with lease ( e.g. , minimum rent payments) and non-lease components ( e.g. , maintenance), which are generally accounted for separately. The Company has not elected the practical expedient to account for lease and non-lease components as one lease component. Management does not expect any recently issued, but not yet effective, accounting standards to have a material effect on its results of operations or financial condition.

Risks and uncertainties

Risks and uncertainties	9 Months Ended
	Sep. 30, 2019
Risks and Uncertainties [Abstract]
Risks and uncertainties	Risks and uncertainties The Company is subject to risks and uncertainties common in the biotechnology and aquaculture industries. Such risks and uncertainties include, but are not limited to: (i) results from current and planned product development studies and trials; (ii) decisions made by the FDA or similar regulatory bodies in other countries with respect to approval and commercial sale of any of the Company’s proposed products; (iii) the commercial acceptance of any products approved for sale and the Company’s ability to manufacture, distribute, and sell for a profit any products approved for sale; (iv) the Company’s ability to obtain the necessary patents and proprietary rights to effectively protect its technologies; and (v) the outcome of any collaborations or alliances entered into by the Company. In addition, as disclosed in “Item 1A. Risk Factors,” below, and in “Item 1A. Risk Factors” in our Annual Report on Form 10‑K for the year ended December 31, 2018, which was filed on March 7, 2019, there are a number of other risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. Concentration of credit risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and certificates of deposit. This risk is minimized by the Company’s policy of investing in financial instruments with short-term maturities issued by highly rated financial institutions. The Company’s cash balances may at times exceed insurance limitations. The Company holds cash balances in bank accounts located in Canada to fund its local operations. These amounts are subject to foreign currency exchange risk, which is mitigated by the Company’s policy to limit the balances held in these accounts. Balances in Canadian bank accounts totaled $242,324 at September 30, 2019 .

Inventory

Inventory	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventory	Inventory Major classifications of inventory are summarized as follows: September 30, December 31, 2019 2018 Feed $ 120,639 $ 24,288 Eggs 65,325 — Packaging — 8,913 Fish in process 291,113 42,908 Total inventory $ 477,077 $ 76,109

Property, plant and equipment

Property, plant and equipment	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment Major classifications of property, plant and equipment are summarized as follows: September 30, December 31, 2019 2018 Land $ 713,703 $ 704,567 Building and improvements 13,119,001 9,244,737 Construction in process 2,010,705 6,091,265 Equipment 11,930,465 9,713,030 Office furniture and equipment 201,194 192,606 Vehicles 27,621 26,832 Total property and equipment $ 28,002,689 $ 25,973,037 Less accumulated depreciation and amortization (3,221,984 ) (2,256,269 ) Property, plant and equipment, net $ 24,780,705 $ 23,716,768 During the quarter ended September 30, 2019 , a significant portion of the Rollo Bay facility was placed in service. As a result, the Company transferred $5.2 million of construction in process to building and improvements and equipment and commenced deprecation of these assets. Remaining in construction in process is $1.7 million for construction costs to complete the farm site and another $374 thousand has been committed.

Accounts payable and accrued li

Accounts payable and accrued liabilities	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities Accounts payable and accrued liabilities include the following: September 30, December 31, 2019 2018 Accounts payable $ 373,775 $ 366,917 Accrued compensation 279,607 223,481 Accrued professional fees and research costs 289,885 185,992 Accrued franchise and excise taxes 91,665 23,678 Accrued construction costs 67,171 13,716 Accrued other 518 11,116 Accounts payable and accrued liabilities $ 1,102,621 $ 824,900

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	Debt The current material terms and conditions of debt outstanding are as follows: Original loan amount Interest Monthly Maturity September 30, 2019 December 31, 2018 ACOA AIF grant (C$2,871,919) 0% Royalties - $ 2,168,873 $ 2,106,840 ACOA term loan (C$337,000) 0% C$3,120 June 2026 188,528 203,735 ACOA term loan (C$500,000) 0% C$4,630 November 2028 377,600 — Kubota Canada Ltd. (C$95,961) 0% C$1,142 January 2025 55,215 61,178 Finance PEI term loan (C$2,717,093) 4% C$16,313 November 2023 1,756,392 1,219,681 Total debt $ 4,546,608 $ 3,591,434 less: current portion (149,069 ) (71,613 ) Long-term debt $ 4,397,539 $ 3,519,821 Estimated principal payments remaining on loan debt are as follows: Year AIF ACOA FPEI Kubota Total 2019 $ — $ 7,069 $ 19,507 $ 2,588 $ 29,164 2020 — 70,234 79,808 10,353 160,395 2021 — 70,234 83,064 10,353 163,651 2022 — 70,234 86,448 10,353 167,035 2023 — 70,234 1,487,565 10,353 1,568,152 Thereafter 2,168,873 278,123 — 11,215 2,458,211 Total $ 2,168,873 $ 566,128 $ 1,756,392 $ 55,215 $ 4,546,608 On March 7, 2019, the Canadian Subsidiary received C $500 thousand under a credit facility with the Atlantic Canada Opportunities Agency (“ACOA”). The proceeds of the loan are to be used to partially finance the construction at the Rollo Bay site. The loan will be repaid over a term of nine years and has a zero percent interest rate. In 2018, the Canadian Subsidiary obtained a new loan from Finance PEI (“FPEI”), which incorporated the existing loan and provides C $2.0 million ( $1.5 million ) of additional funds. As of December 31, 2018, C $1.0 million ( $734 thousand ) had been drawn down. On May 17, 2019, an additional C $700 thousand ( $535 thousand ) had been drawn down. The final C $300 thousand ( $230 thousand ) is anticipated to be drawn down during the fourth quarter of 2019. Payments commenced in June 2019. The loan has an interest rate of 4% and is collateralized by a mortgage executed by the Canadian Subsidiary, which conveys a first security interest in all of its current and acquired assets. The loan is guaranteed by the Parent. Other than these loans, there have been no material changes to the Company’s debt arrangements as disclosed in our annual report on Form 10‑K for the year ended December 31, 2018. The Company recognized interest expense of $44,415 and $15,782 for the nine months ended September 30, 2019 and 2018 , respectively, on its interest-bearing debt.

Leases Leases

Leases Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Leases Lease expense for the nine months ended September 30, 2019 , amounted to $102,385 . The weighted average remaining lease term of the Company’s operating leases was 22.8 years as of September 30, 2019 . Lease payments included in operating cash flows totaled $121,788 for the nine months ended September 30, 2019 . The table below summarizes the Company’s lease obligations and remaining payments at September 30, 2019 : September 30, 2019 January 1, 2019 Lease Type End Date Remaining Years Remaining Payments Lease Liability Remaining Payments Lease Liability Maynard Office Lease Operating Mar 2023 3.5 $ 231,568 $ 198,758 $ 278,414 $ 234,685 Panama Farm Lease Operating Apr 2019 0 — — 60,000 59,013 Indiana Auto Lease Operating Feb 2021 1.4 7,210 6,656 10,842 9,897 Indiana Well Lease Operating Dec 2048 29.3 706,110 224,640 717,420 228,844 Total leases $ 944,888 $ 430,054 $ 1,066,676 $ 532,439 Less: current portion (84,453 ) (61,315 ) (142,780 ) (117,345 ) Long-term leases $ 860,435 $ 368,739 $ 923,896 $ 415,094 Remaining payments under leases are as follows at September 30, 2019: Year Office Auto Well Amount 2019 $ 16,011 $ 1,211 $ 3,770 $ 20,992 2020 64,637 4,842 15,532 85,011 2021 66,416 1,157 15,998 83,571 2022 67,602 — 16,478 84,080 2023 16,902 — 16,972 33,874 Thereafter — — 637,360 637,360 Total Lease Payments $ 231,568 $ 7,210 $ 706,110 $ 944,888

Stockholders' equity

Stockholders' equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Recent issuances On March 21, 2019, the Company completed a public offering of 3,345,282 Common Shares. Net proceeds to the Company were $6.6 million after deducting discounts, fees, and expenses. On April 5, 2019, the Company completed a public offering of 2,554,590 Common Shares. Net proceeds to the Company were $5.2 million after deducting discounts, fees, and expenses. On April 17, 2019, the Company issued 346,488 Common Shares in conjunction with the overallotment exercise by the Company’s investment banker. Net proceeds to the Company were $696 thousand after deducting discounts, fees, and expenses. Warrants The following table summarizes information about outstanding warrants at September 30, 2019 : Number of warrant shares Weighted average exercise price Outstanding at December 31, 2018 1,745,868 $3.25 Exercised (83,564 ) 3.25 Outstanding at September 30, 2019 1,662,304 $3.25 Exercisable at September 30, 2019 1,662,304 $3.25 During the nine months ended September 30, 2019 , the Company issued 83,564 Common Shares at $3.25 per share in conjunction with the exercise of warrants, with total proceeds of $272 thousand . Share-based compensation Restricted stock A summary of the Company’s shares of restricted stock as of September 30, 2019 , is as follows: Shares Weighted average grant date fair value Balance at December 31, 2018 8,867 $3.51 Granted 176,561 2.13 Vested (127,133 ) 2.19 Balance at September 30, 2019 58,295 $2.21 During the nine months ended September 30, 2019 and 2018 , the Company expensed $279,026 and $20,421 , respectively, related to the restricted stock awards. At September 30, 2019 , the balance of unearned share-based compensation to be expensed in future periods related to the restricted stock awards is $128,307 . The period over which the unearned share-based compensation is expected to be earned is approximately 2.5 years. Stock options The Company’s option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2018 339,964 $7.09 Issued 278,500 2.21 Expired (79,539 ) 3.41 Outstanding at September 30, 2019 538,925 $5.11 Exercisable at September 30, 2019 401,847 $5.99 Unless otherwise indicated, options issued to employees, members of the Board of Directors, and non-employees are vested over one to three years and are exercisable for a term of ten years from the date of issuance. The fair values of stock option grants to employees and members of the Board of Directors during 2019 were measured on the date of grant using Black-Scholes, with the following weighted average assumptions: March 2019 April 2019 June 2019 Expected volatility 89% 94% 96% Risk free interest rate 2.53% 2.28% 1.85% Expected dividend yield 0% 0% 0% Expected life (in years) 5 5 5 The weighted average fair value of stock options granted during the nine months ended September 30, 2019 , was $ 2.21 . The total intrinsic value of all options outstanding was $80,305 and $0 at September 30, 2019 , and December 31, 2018 , respectively. The total intrinsic value of exercisable options was $41,492 and $0 at September 30, 2019 , and December 31, 2018 , respectively. The following table summarizes information about options outstanding and exercisable at September 30, 2019 : Weighted average exercise price of outstanding options Number of options outstanding Weighted average remaining estimated life (in years) Number of options exercisable Weighted average exercise price of outstanding and exercisable options $2.50 - $5.70 403,663 9.1 270,120 $6.90 - $9.60 52,841 3.0 52,841 $10.50 - $10.80 4,000 4.4 4,000 $14.20 - $23.40 78,421 6.5 74,886 538,925 401,847 $5.99 Total share-based compensation on stock options amounted to $374,426 and $171,261 for the nine months ended September 30, 2019 and 2018 , respectively. At September 30, 2019 , the balance of unearned share-based compensation to be expensed in future periods related to unvested share-based awards was $229,807 . The period over which the unearned share-based compensation is expected to be earned is approximately 0.8 years. During the period ended June 30, 2019, the Company recognized share based compensation of $134,258 related to the accelerated vesting and exercisable term change for options to purchase an aggregate of 153,940 shares for the Company’s former CEO, who retired June 30, 2019. Each option granted was revalued as of June 30, 2019, using the following Black-Scholes values to determine the incremental charges for the option modification: expected volatility of 97% , risk free interest rate of 1.71% to 1.92% , expected dividend yield of 0.0% , and expected life of 1.5 to 5 years. The following table summarizes the expense related to the options revalued at June 30, 2019: Expense Grant date Number of options Previous Accelerated Incremental Total 1/11/2011 16,667 $ 109,769 $ — $ 11,782 $ 121,551 1/20/2014 6,667 120,712 — 7,621 128,333 2/27/2018 60,606 99,738 — 12,313 112,051 4/21/2017 20,000 70,346 20,736 13,485 104,567 4/30/2019 50,000 13,453 67,047 1,274 81,774 153,940 $ 414,018 $ 87,783 $ 46,475 $ 548,276

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies The Company recognizes and discloses commitments when it enters into executed contractual obligations with other parties. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. See Note 5 for commitments related to our renovation and construction costs. There have been no other material changes to the commitments and contingencies disclosed in our Annual Report on Form 10‑K as of and for the year ended December 31, 2018.

Related Party Collaboration Agr

Related Party Collaboration Agreement	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Collaboration Agreement	Related Party Collaboration Agreement In February 2013, the Company entered into an Exclusive Channel Collaboration agreement (“ECC”) with Intrexon Corporation (“Intrexon”) pursuant to which the Company will use Intrexon’s UltraVector and other technology platforms to develop and commercialize additional bioengineered traits in finfish for human consumption. Total Intrexon service costs incurred under the terms of this agreement for the nine months ended September 30, 2019 and 2018 , amounted to $18,550 and $190,195 , respectively, and are included as a component of research and development expense in our Consolidated Statements of Operations and Comprehensive Loss. For the three months ended September 30, 2019 and 2018 , service costs incurred amounted to $2,816 and $54,154 , respectively. Included in accounts payable and accrued liabilities at September 30, 2019 , and December 31, 2018 , are amounts due to Intrexon under the ECC totaling $1,000 and $800 , respectively.

Basis of presentation (Policies

Basis of presentation (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation	The unaudited interim consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC; and AquaBounty Brasil Participações Ltda. All inter-company transactions and balances have been eliminated upon consolidation.
Basis of presentation	The unaudited interim consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2018 . The unaudited interim consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of September 30, 2019 , and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.
Net loss per share	Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Basic net loss is based solely on the number of Common Shares outstanding during the period. Fully diluted net loss per share includes the number of shares of common stock issuable upon the exercise of warrants and options with an exercise price less than the fair value of the common stock. Since the Company is reporting a net loss for all periods presented, all potential common shares are considered anti‑dilutive and are excluded from the calculation of diluted net loss per share.
Accounting Pronouncements	In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016‑02, “Leases,” which requires a lessee to recognize lease liabilities for the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and right-of-use assets, representing the lessee’s right to use, or control the use of, specified assets for the lease term. The ASU is effective for fiscal years beginning after December 15, 2018. The Company adopted FASB ASU 2016-02 for lease accounting on January 1, 2019 and recognized a lease liability of $532 thousand and a corresponding right-of-use asset of $512 thousand . Management calculated the lease liability based on the net present value of the remaining lease payments on the date of adoption using a weighted average discount rate of 8% . As most of the Company’s leases did not provide an implicit interest rate, management used an estimated incremental borrowing rate. The adoption did not result in any cumulative-effect adjustment to beginning retained earnings. The Company leases certain facilities, property, and equipment under noncancelable operating leases. A determination is made if an arrangement is a lease at its inception, and leases with an initial term of twelve months or less are not recorded on the balance sheet. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. For operating leases, expense is recognized on a straight-line basis over the lease term. The Company has agreements with lease ( e.g. , minimum rent payments) and non-lease components ( e.g. , maintenance), which are generally accounted for separately. The Company has not elected the practical expedient to account for lease and non-lease components as one lease component. Management does not expect any recently issued, but not yet effective, accounting standards to have a material effect on its results of operations or financial condition.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Major classifications of inventory	Major classifications of inventory are summarized as follows: September 30, December 31, 2019 2018 Feed $ 120,639 $ 24,288 Eggs 65,325 — Packaging — 8,913 Fish in process 291,113 42,908 Total inventory $ 477,077 $ 76,109

Property, plant and equipment (

Property, plant and equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Major classifications of property, plant and equipment	Major classifications of property, plant and equipment are summarized as follows: September 30, December 31, 2019 2018 Land $ 713,703 $ 704,567 Building and improvements 13,119,001 9,244,737 Construction in process 2,010,705 6,091,265 Equipment 11,930,465 9,713,030 Office furniture and equipment 201,194 192,606 Vehicles 27,621 26,832 Total property and equipment $ 28,002,689 $ 25,973,037 Less accumulated depreciation and amortization (3,221,984 ) (2,256,269 ) Property, plant and equipment, net $ 24,780,705 $ 23,716,768

Accounts payable and accrued _2

Accounts payable and accrued liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	Accounts payable and accrued liabilities include the following: September 30, December 31, 2019 2018 Accounts payable $ 373,775 $ 366,917 Accrued compensation 279,607 223,481 Accrued professional fees and research costs 289,885 185,992 Accrued franchise and excise taxes 91,665 23,678 Accrued construction costs 67,171 13,716 Accrued other 518 11,116 Accounts payable and accrued liabilities $ 1,102,621 $ 824,900

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Material terms and conditions of outstanding debt	The current material terms and conditions of debt outstanding are as follows: Original loan amount Interest Monthly Maturity September 30, 2019 December 31, 2018 ACOA AIF grant (C$2,871,919) 0% Royalties - $ 2,168,873 $ 2,106,840 ACOA term loan (C$337,000) 0% C$3,120 June 2026 188,528 203,735 ACOA term loan (C$500,000) 0% C$4,630 November 2028 377,600 — Kubota Canada Ltd. (C$95,961) 0% C$1,142 January 2025 55,215 61,178 Finance PEI term loan (C$2,717,093) 4% C$16,313 November 2023 1,756,392 1,219,681 Total debt $ 4,546,608 $ 3,591,434 less: current portion (149,069 ) (71,613 ) Long-term debt $ 4,397,539 $ 3,519,821
Estimated principal payments on loan debt	Estimated principal payments remaining on loan debt are as follows: Year AIF ACOA FPEI Kubota Total 2019 $ — $ 7,069 $ 19,507 $ 2,588 $ 29,164 2020 — 70,234 79,808 10,353 160,395 2021 — 70,234 83,064 10,353 163,651 2022 — 70,234 86,448 10,353 167,035 2023 — 70,234 1,487,565 10,353 1,568,152 Thereafter 2,168,873 278,123 — 11,215 2,458,211 Total $ 2,168,873 $ 566,128 $ 1,756,392 $ 55,215 $ 4,546,608

Leases Leases (Tables)

Leases Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Operating lease obligations and remaining payments	The table below summarizes the Company’s lease obligations and remaining payments at September 30, 2019 : September 30, 2019 January 1, 2019 Lease Type End Date Remaining Years Remaining Payments Lease Liability Remaining Payments Lease Liability Maynard Office Lease Operating Mar 2023 3.5 $ 231,568 $ 198,758 $ 278,414 $ 234,685 Panama Farm Lease Operating Apr 2019 0 — — 60,000 59,013 Indiana Auto Lease Operating Feb 2021 1.4 7,210 6,656 10,842 9,897 Indiana Well Lease Operating Dec 2048 29.3 706,110 224,640 717,420 228,844 Total leases $ 944,888 $ 430,054 $ 1,066,676 $ 532,439 Less: current portion (84,453 ) (61,315 ) (142,780 ) (117,345 ) Long-term leases $ 860,435 $ 368,739 $ 923,896 $ 415,094
Remaining payments under leases	Remaining payments under leases are as follows at September 30, 2019: Year Office Auto Well Amount 2019 $ 16,011 $ 1,211 $ 3,770 $ 20,992 2020 64,637 4,842 15,532 85,011 2021 66,416 1,157 15,998 83,571 2022 67,602 — 16,478 84,080 2023 16,902 — 16,972 33,874 Thereafter — — 637,360 637,360 Total Lease Payments $ 231,568 $ 7,210 $ 706,110 $ 944,888

Stockholders' equity (Tables)

Stockholders' equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of outstanding warrants	The following table summarizes information about outstanding warrants at September 30, 2019 : Number of warrant shares Weighted average exercise price Outstanding at December 31, 2018 1,745,868 $3.25 Exercised (83,564 ) 3.25 Outstanding at September 30, 2019 1,662,304 $3.25 Exercisable at September 30, 2019 1,662,304 $3.25
Schedule of restricted stock activity	A summary of the Company’s shares of restricted stock as of September 30, 2019 , is as follows: Shares Weighted average grant date fair value Balance at December 31, 2018 8,867 $3.51 Granted 176,561 2.13 Vested (127,133 ) 2.19 Balance at September 30, 2019 58,295 $2.21
Schedule of stock option activity	The Company’s option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2018 339,964 $7.09 Issued 278,500 2.21 Expired (79,539 ) 3.41 Outstanding at September 30, 2019 538,925 $5.11 Exercisable at September 30, 2019 401,847 $5.99
Fair value of stock option grants	The fair values of stock option grants to employees and members of the Board of Directors during 2019 were measured on the date of grant using Black-Scholes, with the following weighted average assumptions: March 2019 April 2019 June 2019 Expected volatility 89% 94% 96% Risk free interest rate 2.53% 2.28% 1.85% Expected dividend yield 0% 0% 0% Expected life (in years) 5 5 5
Summary of options outstanding and exercisable	The following table summarizes information about options outstanding and exercisable at September 30, 2019 : Weighted average exercise price of outstanding options Number of options outstanding Weighted average remaining estimated life (in years) Number of options exercisable Weighted average exercise price of outstanding and exercisable options $2.50 - $5.70 403,663 9.1 270,120 $6.90 - $9.60 52,841 3.0 52,841 $10.50 - $10.80 4,000 4.4 4,000 $14.20 - $23.40 78,421 6.5 74,886 538,925 401,847 $5.99
Summary of expense related to options revalued	The following table summarizes the expense related to the options revalued at June 30, 2019: Expense Grant date Number of options Previous Accelerated Incremental Total 1/11/2011 16,667 $ 109,769 $ — $ 11,782 $ 121,551 1/20/2014 6,667 120,712 — 7,621 128,333 2/27/2018 60,606 99,738 — 12,313 112,051 4/21/2017 20,000 70,346 20,736 13,485 104,567 4/30/2019 50,000 13,453 67,047 1,274 81,774 153,940 $ 414,018 $ 87,783 $ 46,475 $ 548,276

Basis of presentation (Details)

Basis of presentation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash balance	$ 6,412,921	$ 1,030,671		$ 2,990,196	$ 492,861
Proceeds from issuance of equity	12,395,348	$ 10,616,048
Right of use asset	413,235		$ 512,000	$ 0
Lease liability	$ 430,054		$ 532,439
Weighted average discount rate of remaining lease payments			8.00%

Risks and uncertainties (Detail

Risks and uncertainties (Details)	Sep. 30, 2019USD ($)
Concentration of credit risk | Cash | Canada
Concentration Risk [Line Items]
Balance in Canadian bank accounts	$ 242,324

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Inventory	$ 477,077	$ 76,109
Feed
Inventory [Line Items]
Inventory	120,639	24,288
Eggs
Inventory [Line Items]
Inventory	65,325	0
Packaging
Inventory [Line Items]
Inventory	0	8,913
Fish in process
Inventory [Line Items]
Inventory	$ 291,113	$ 42,908

Property, plant and equipment -

Property, plant and equipment - Schedule of property, plant and equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 28,002,689	$ 25,973,037
Less accumulated depreciation and amortization	(3,221,984)	(2,256,269)
Property, plant and equipment, net	24,780,705	23,716,768
Land
Property, Plant and Equipment [Line Items]
Total property and equipment	713,703	704,567
Building and improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	13,119,001	9,244,737
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	2,010,705	6,091,265
Equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	11,930,465	9,713,030
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	201,194	192,606
Vehicles
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 27,621	$ 26,832

Property, plant and equipment_2

Property, plant and equipment - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Construction in process	$ 28,002,689	$ 25,973,037
Capital Additions | Rollo Bay farm site
Property, Plant and Equipment [Line Items]
Property, Plant, and equipment cost commitment	374,000
Buildings and Improvements and Equipment | Rollo Bay farm site
Property, Plant and Equipment [Line Items]
Construction in process	5,200,000
Construction in process
Property, Plant and Equipment [Line Items]
Construction in process	2,010,705	$ 6,091,265
Construction in process | Rollo Bay farm site
Property, Plant and Equipment [Line Items]
Construction in process	$ 1,700,000

Accounts payable and accrued _3

Accounts payable and accrued liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 373,775	$ 366,917
Accrued compensation	279,607	223,481
Accrued professional fees and research costs	289,885	185,992
Accrued franchise and excise taxes	91,665	23,678
Accrued construction costs	67,171	13,716
Accrued other	518	11,116
Accounts payable and accrued liabilities	$ 1,102,621	$ 824,900

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details)	9 Months Ended
	Sep. 30, 2019CAD ($)	Sep. 30, 2019USD ($)	Mar. 07, 2019CAD ($)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Total Debt		$ 4,546,608		$ 3,591,434
less: current portion		(149,069)		(71,613)
Long-term debt		4,397,539		3,519,821
ACOA AIF Grant (C$2,871,919)
Debt Instrument [Line Items]
Total Debt		2,168,873
Kubota Canada Ltd (C$95,961)
Debt Instrument [Line Items]
Total Debt		55,215
Finance PEI term loan (C$2,717,093)
Debt Instrument [Line Items]
Total Debt		$ 1,756,392
Government grant | ACOA AIF Grant (C$2,871,919)
Debt Instrument [Line Items]
Original loan amount	$ 2,871,919
Interest rate	0.00%	0.00%
Total Debt		$ 2,168,873		2,106,840
Term loan | ACOA term loan (C$337,000)
Debt Instrument [Line Items]
Original loan amount	$ 337,000
Interest rate	0.00%	0.00%
Monthly repayment	$ 3,120
Total Debt		$ 188,528		203,735
Term loan | ACOA term loan (C$500,000)
Debt Instrument [Line Items]
Original loan amount	$ 500,000		$ 500,000
Interest rate	0.00%	0.00%	0.00%
Monthly repayment	$ 4,630
Total Debt		$ 377,600		0
Term loan | Kubota Canada Ltd (C$95,961)
Debt Instrument [Line Items]
Original loan amount	$ 95,961
Interest rate	0.00%	0.00%
Monthly repayment	$ 1,142
Total Debt		$ 55,215		61,178
Term loan | Finance PEI term loan (C$2,717,093)
Debt Instrument [Line Items]
Original loan amount	$ 717,093
Interest rate	4.00%	4.00%
Monthly repayment	$ 16,313
Total Debt		$ 1,756,392		$ 1,219,681

Debt - Debt Maturities (Details

Debt - Debt Maturities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Year
2019	$ 29,164
2020	160,395
2021	163,651
2022	167,035
2023	1,568,152
Thereafter	2,458,211
Total	4,546,608	$ 3,591,434
Atlantic Canada Opportunities Agency AIF Grant
Year
2019	0
2020	0
2021	0
2022	0
2023	0
Thereafter	2,168,873
Total	2,168,873
Atlantic Canada Opportunities Agency Term Loan
Year
2019	7,069
2020	70,234
2021	70,234
2022	70,234
2023	70,234
Thereafter	278,123
Total	566,128
PEI Finance Term Loan
Year
2019	19,507
2020	79,808
2021	83,064
2022	86,448
2023	1,487,565
Thereafter	0
Total	1,756,392
Kubota Canada Ltd
Year
2019	2,588
2020	10,353
2021	10,353
2022	10,353
2023	10,353
Thereafter	11,215
Total	$ 55,215

Debt - Additional Information (

Debt - Additional Information (Details)

1 Months Ended

9 Months Ended

Mar. 31, 2019

Sep. 30, 2019USD ($)

Sep. 30, 2018USD ($)

Sep. 30, 2019CAD ($)

Sep. 30, 2019USD ($)

May 17, 2019CAD ($)

May 17, 2019USD ($)

Mar. 07, 2019CAD ($)

Dec. 31, 2018CAD ($)

Dec. 31, 2018USD ($)

Oct. 16, 2018CAD ($)

Oct. 16, 2018USD ($)

Debt Instrument [Line Items]

Interest expense on debt

$ 44,415

$ 15,782

Term loan | ACOA term loan (C$500,000)

Debt Instrument [Line Items]

Original loan amount

$ 500,000

$ 500,000

Debt instrument term (in years)

9 years

Interest rate

0.00%

0.00%

0.00%

Term loan | PEI Finance Term Loan October 2018 [Member]

Debt Instrument [Line Items]

Original loan amount

$ 2,000,000

$ 1,500,000

Interest rate

4.00%

4.00%

Funds drawn on loan

$ 300,000

$ 230,000

$ 700,000

$ 535,000

$ 1,000,000

$ 734,000

Leases Lease Obligations (Detai

Leases Lease Obligations (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019
Remaining Years	22 years 9 months 18 days
Remaining Payments	$ 944,888	$ 1,066,676
Lease liability	430,054	532,439
Less: remaining payments, current portion	(84,453)	(142,780)
Less: lease liability, current portion	(61,315)	(117,345)
Remaining payments, long-term leases	860,435	923,896
Lease liability, long-term leases	$ 368,739	415,094
Maynard Office Lease
Remaining Years	3 years 6 months
Remaining Payments	$ 231,568	278,414
Lease liability	$ 198,758	234,685
Panama Farm Lease
Remaining Years	0 days
Remaining Payments	$ 0	60,000
Lease liability	$ 0	59,013
Indiana auto lease
Remaining Years	1 year 5 months 1 day
Remaining Payments	$ 7,210	10,842
Lease liability	$ 6,656	9,897
Indiana well lease
Remaining Years	29 years 3 months 7 days
Remaining Payments	$ 706,110	717,420
Lease liability	$ 224,640	$ 228,844

Leases Remaining Lease Payments

Leases Remaining Lease Payments (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
2019	$ 20,992
2020	85,011
2021	83,571
2022	84,080
2023	33,874
Thereafter	637,360
Total Lease Payments	944,888	$ 1,066,676
Office
Lessee, Lease, Description [Line Items]
2019	16,011
2020	64,637
2021	66,416
2022	67,602
2023	16,902
Thereafter	0
Total Lease Payments	231,568
Auto
Lessee, Lease, Description [Line Items]
2019	1,211
2020	4,842
2021	1,157
2022	0
2023	0
Thereafter	0
Total Lease Payments	7,210
Well
Lessee, Lease, Description [Line Items]
2019	3,770
2020	15,532
2021	15,998
2022	16,478
2023	16,972
Thereafter	637,360
Total Lease Payments	$ 706,110

Leases Additional Information (

Leases Additional Information (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Additional Information [Abstract]
Lease expense	$ 102,385
Weighted average remaining lease term, all operating leases	22 years 9 months 18 days
Lease payments	$ 121,788

Stockholders' equity - Recent I

Stockholders' equity - Recent Issuances (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2019	Mar. 31, 2019
March 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from common shares offering		$ 6.6
April 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from common shares offering	$ 5.2
Overallotment exercise [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from common shares offering	$ 0.7
Common Stock | March 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued (in shares)		3,345,282
Common Stock | April 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued (in shares)	2,554,590
Common Stock | Overallotment exercise [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued (in shares)	346,488

Stockholders' equity - Warrants

Stockholders' equity - Warrants (Details) - Warrant $ / shares in Units, $ in Thousands	6 Months Ended	9 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2019$ / sharesshares
Number of options
Outstanding, beginning balance (in shares) | shares	1,745,868	1,745,868
Exercised (in shares) | shares		(83,564)
Outstanding, ending balance (in shares) | shares		1,662,304
Exercisable (in shares) | shares		1,662,304
Weighted average exercise price
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 3.25	$ 3.25
Exercised (in dollars per share) | $ / shares		3.25
Outstanding, ending balance (in dollars per share) | $ / shares		3.25
Exercisable (in dollars per share) | $ / shares		$ 3.25
Proceeds from warrant exercised | $	$ 272

Stockholders' equity - Restrict

Stockholders' equity - Restricted stock activity (Details) - Restricted Stock - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Shares
Beginning balance (in shares)	8,867
Granted (in shares)	176,561
Vested (in shares)	(127,133)
Ending balance (in shares)	58,295
Weighted average grant date fair value
Beginning balance (in dollars per share)	$ 3.51
Granted (in dollars per share)	2.13
Vested (in dollars per share)	2.19
Ending balance (in dollars per share)	$ 2.21
Expense related to restricted stock awards	$ 279,026	$ 20,421
Future expected expense related to restricted stock awards	$ 128,307
Period of recognition	2 years 6 months

Stockholders' equity - Stock op

Stockholders' equity - Stock option activity (Details) - Employee Stock Option	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of options
Outstanding, beginning balance (in shares) | shares	339,964
Issued (in shares) | shares	278,500
Expired (in shares) | shares	(79,539)
Outstanding, ending balance (in shares) | shares	538,925
Exercisable (in shares) | shares	401,847
Weighted average exercise price
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 7.09
Issued (in dollars per share) | $ / shares	2.21
Expired (in dollars per share) | $ / shares	3.41
Outstanding, ending balance (in dollars per share) | $ / shares	5.11
Exercisable (in dollars per share) | $ / shares	$ 5.99
Stock options, exercisable term (in years)	10 years
Minimum
Weighted average exercise price
Stock options, vesting period (in years)	1 year
Maximum
Weighted average exercise price
Stock options, vesting period (in years)	3 years

Stockholders' equity - Weighted

Stockholders' equity - Weighted Average Assumptions (Details) - Employee Stock Option	1 Months Ended
	Jun. 30, 2019	Apr. 30, 2019	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	96.00%	94.00%	89.00%
Risk free interest rate	1.85%	2.28%	2.53%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life (in years)	5 years	5 years	5 years

Stockholders' equity - Summary

Stockholders' equity - Summary of options outstanding and exercisable (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	538,925
Number of options exercisable (in shares)	401,847
Weighted average exercise price of outstanding and exercisable options (in dollars per share) | $ / shares	$ 5.99
$2.50 - $5.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	403,663
Weighted average remaining estimated life (in years)	9 years 1 month 6 days
Number of options exercisable (in shares)	270,120
$6.90 - $9.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	52,841
Weighted average remaining estimated life (in years)	3 years
Number of options exercisable (in shares)	52,841
$10.50 - $10.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	4,000
Weighted average remaining estimated life (in years)	4 years 4 months 24 days
Number of options exercisable (in shares)	4,000
$14.20 - $23.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	78,421
Weighted average remaining estimated life (in years)	6 years 6 months
Number of options exercisable (in shares)	74,886
Minimum | $2.50 - $5.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	$ 2.50
Minimum | $6.90 - $9.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	6.90
Minimum | $10.50 - $10.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	10.50
Minimum | $14.20 - $23.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	14.20
Maximum | $2.50 - $5.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	5.70
Maximum | $6.90 - $9.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	9.60
Maximum | $10.50 - $10.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	10.80
Maximum | $14.20 - $23.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) | $ / shares	$ 23.40

Stockholders' equity - Share-ba

Stockholders' equity - Share-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation			$ 653,452	$ 191,682
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 134,258
Number of options		153,940
Expected volatility		97.00%
Expected dividend yield		0.00%
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Grant Date 1/11/2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options		16,667
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Grant Date 1/20/2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options		6,667
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Grant Date 2/27/2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options		60,606
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Grant Date 4/21/2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options		20,000
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Grant Date 4/30/2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options		50,000
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 414,018
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member] | Grant Date 1/11/2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		109,769
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member] | Grant Date 1/20/2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		120,712
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member] | Grant Date 2/27/2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		99,738
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member] | Grant Date 4/21/2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		70,346
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Previously recognized expense [Member] | Grant Date 4/30/2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		13,453
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		87,783
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member] | Grant Date 1/11/2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		0
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member] | Grant Date 1/20/2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		0
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member] | Grant Date 2/27/2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		0
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member] | Grant Date 4/21/2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		20,736
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Accelerated vesting expense [Member] | Grant Date 4/30/2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		67,047
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		46,475
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member] | Grant Date 1/11/2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		11,782
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member] | Grant Date 1/20/2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		7,621
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member] | Grant Date 2/27/2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		12,313
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member] | Grant Date 4/21/2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		13,485
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Incremental vesting expense [Member] | Grant Date 4/30/2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		1,274
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		548,276
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member] | Grant Date 1/11/2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		121,551
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member] | Grant Date 1/20/2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		128,333
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member] | Grant Date 2/27/2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		112,051
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member] | Grant Date 4/21/2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		104,567
Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member] | Total of previous, accelerated and incremental expense [Member] | Grant Date 4/30/2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 81,774
Minimum | Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.71%
Expected life (in years)		1 year 6 months
Maximum | Chief Executive Officer [Member] | Accelerated share-based compensation summary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.92%
Expected life (in years)	5 years

Stockholders' equity - Addition

Stockholders' equity - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options granted (in dollars per share)	$ 2.21
Intrinsic value of options outstanding	$ 80,305		$ 0
Intrinsic value of options exercisable	41,492		$ 0
Share-based compensation	$ 653,452	$ 191,682
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of recognition	9 months 18 days
Share-based compensation	$ 374,426	$ 171,261
Unearned share-based compensation expense	$ 229,807

Related Party Collaboration A_2

Related Party Collaboration Agreement (Details) - Intrexon Corporation - ECC Agreement - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Accounts Payable and Accrued Liabilities
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities due to related party	$ 1,000		$ 1,000		$ 800
Research and Development Expense
Related Party Transaction [Line Items]
Service costs incurred	$ 2,816	$ 54,154	$ 18,550	$ 190,195